Ovarian Serous Adenocarcinoma
Back to Diseases List
Associated Genetic Biomarkers
NCI Definition: An adenocarcinoma that arises from the ovary and is characterized by the presence of malignant epithelial cells that, in well differentiated tumors, resemble the epithelium of the fallopian tube or, in poorly differentiated tumors, show anaplastic features and marked nuclear atypia. 
Ovarian serous adenocarcinomas most frequently harbor alterations in TP53, CCNE1, KRAS, BRCA1, and NF1 .
TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, TP53 Exon 5 Mutation, and TP53 Exon 8 Mutation are the most common alterations in ovarian serous adenocarcinoma .
There are 10 clinical trials for ovarian serous adenocarcinoma, of which 9 are open and 1 is completed or closed. Of the trials that contain ovarian serous adenocarcinoma as an inclusion criterion, 1 is early phase 1 (1 open), 2 are phase 1 (1 open), 5 are phase 1/phase 2 (5 open), and 2 are phase 2 (2 open).
Homologous and MSLN are the most frequent gene inclusion criteria for ovarian serous adenocarcinoma clinical trials .
Bevacizumab, cyclophosphamide, and fludarabine are the most common interventions in ovarian serous adenocarcinoma clinical trials.
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.